CHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - AGENUS INC

Financial Performance:

• Secured approximately $850 million in financing in July to support the strategic pivot, which resulted in a stock increase of roughly double in a single trading session.
• Generates revenue from external marketing authorizations and paid access programs (specifically in France for reimbursed therapy and Armenia for advanced metastatic MSS colorectal cancer), though these are not the primary value drivers.
• Financing includes a tranche structure where the enrollment of the 60th patient in the "Robin" trial is anticipated to trigger warrants generating an additional $85 million in proceeds if fully exercised.
• Reduced capital expenditure burden by halting funding for the late-line metastatic MSS setting ("Batman" program) to concentrate resources on the Phase 3 neoadjuvant trial.

Guidance and Future Outlook:

• Trial Timeline: First patient enrollment expected in Q1 2027; interim pathologic response data anticipated in Q4 2027 based on the first 100 patients; interim event-free survival (EFS) data expected in the second half of 2029; final EFS analysis expected in the second half of 2030.
• Market Potential: Estimated total addressable market (TAM) in the U.S. of approximately 30,000 newly diagnosed patients annually, potentially translating to ~$7 billion in annual U.S. sales if the trial succeeds.
• Success Criteria: Management anticipates a hazard ratio of at least 0.65 (representing a 35% improvement in recurrence rates) and significant de-escalation of chemotherapy and radiation.
• Future Development: Plans to release long-term survival data and data on the Bot-T797 combination at major oncology conferences (ESMO, SITC) to support trial enrollment.

Business Segments and Product Lines:

• Strategic Pivot: Decisively shifted focus from the late-line metastatic MSS setting to the high-risk stage II/III neoadjuvant MSS colorectal cancer setting (designated as the "Robin" trial) as the sole registration focus.
• Pipeline Status: The "Robin" Phase 3 trial aims to treat patients prior to surgery to improve disease-free survival and reduce the need for adjuvant chemotherapy and mutilating surgeries (e.g., ostomies).
• Data Generation: Leveraging data from completed NEST and Unicorn trials (showing no recurrences in ~40 patients vs. expected 25% recurrence with standard care) to drive conviction for the neoadjuvant setting.
• Global Access: Maintained compassionate access programs in ~30 countries and secured reimbursement in France for refractory MSS colorectal cancer, sarcoma, and ovarian cancers to ensure patient access while awaiting U.S. approval.
• Targeted Therapy: Focusing on the combination of the company's therapy with Bot-T797 and evaluating the necessity of CTLA-4 inhibitors in dMMR/MSI-High settings, where PD-1 monotherapy already shows high efficacy.

Market and Competitive Landscape:

• Competitive Advantage: Differentiates through the potential to cure a subset of patients in the neoadjuvant setting and significantly reduce toxicity/undertreatment compared to standard chemotherapy.
• Enrollment Dynamics: Anticipates rapid ramp-up in trial enrollment once 2027 pathologic response data confirms high rates of major pathological response (MPR) and pathologic complete response (pCR).
• Investor Sentiment: Recent financing and strategic clarity have generated market enthusiasm, despite initial disappointment regarding the cessation of the late-line program.
• Market Need: Addresses an unmet need in MSS colon cancer where resistance to immunotherapy is a barrier, aiming to change the standard of care by de-escalating chemotherapy.

Risks and Challenges:

• Enrollment Resistance: Initial enrollment may face barriers as patients and physicians are currently prioritizing immediate access to therapy for refractory disease over experimental neoadjuvant trials.
• Data Validation: While early NEST/Unicorn data is compelling, the final EFS hazard ratio and long-term survival benefits must be confirmed in the full Phase 3 "Robin" trial; cure cannot be declared without sufficient maturity.
• Investor/Scientist Relations: The decision to halt the late-line program caused frustration among investigative sites and investors who felt a break was abrupt, though management asserts trust remains intact.
• Regulatory Pathway: No specific accelerated approval strategy is currently defined for the U.S. neoadjuvant setting; the company emphasizes standard regulatory pathways to ensure availability.
• Resource Constraints: Managing two concurrent Phase 3 trials (late-line and neoadjuvant) was deemed resource-prohibitive for a mid-sized biotech, forcing a choice that carries the risk of delayed patient access in the late-line setting.

Management Commentary and Tone:

• Confidence: Management expressed strong conviction in the scientific rationale for the neoadjuvant setting, citing biological plausibility and the potential to "cure" patients with a short treatment course.
• Tone: Confident but transparent about the difficulty of the strategic pivot; openly acknowledged the frustration caused to the medical community and investors by the termination of the late-line program.
• Strategic Clarity: Emphasized that resources are best utilized where the "profoundest impact on patients" can be made, prioritizing the prevention of recurrence over treating end-stage disease.
• Collaboration: Highlighted strong relationships with key investigators (e.g., Dr. Schlechter) who remain enthusiastic about the "Robin" trial despite earlier setbacks.

Analyst Questions and Answers:

• Q: Why is the earlier setting better scientifically/regulatorily? A: It offers the best biological opportunity to prevent recurrence, allows for organ preservation/de-escalation of surgery/chemo, and addresses a larger patient population than the late-line setting.
• Q: What role does the 2027 pathologic response interim play? A: It serves as a confidence generator and catalyst for enrollment/investors, demonstrating a strong correlation between pCR and EFS, but is not a gating milestone for approval.
• Q: How do U.S. investors weigh ex-U.S. approvals? A: These are validators of global demand and safety (particularly in France), but the primary value driver remains the U.S. Phase 3 trial success.
• Q: Is CTLA-4 needed for dMMR/MSI-High neoadjuvant? A: Management is skeptical, noting existing data for PD-1 alone (e.g., NIBL) shows near 100% disease-free survival, suggesting resources are better spent on the MSS setting.
• Q: How did investigators react to stopping the late-line program? A: They were initially "pissed" and disappointed due to the lack of options for refractory patients, but management has successfully managed relationships to ensure "Robin" site selection remains rigorous and committed.

Other Key Points:

• NIST and Unicorn Data: Published data shows no recurrences in the neoadjuvant cohort over 2-3 years, a stark contrast to the ~25% recurrence rate in standard of care.
• Safety Profile: The neoadjuvant therapy is characterized by a short treatment course (4-6 weeks) and a manageable safety profile (<5% Grade 3A adverse events).
• Catalyst Alignment: The financing tranche structure is explicitly designed to align with trial milestones (60th patient enrollment) to ensure capital availability at critical value inflection points.
• Future Data Releases: Upcoming presentations at ESMO Madrid (regarding NEST, DMMR, and NIMR) and SITC in November will provide further data on long-term survival and combination therapies.